5 completed, 4 recruiting, 1 terminated. 9 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Recruiting 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow PEG-IFNα: new trials by email Literature Review of PEG-IFNα trials Research Report on PEG-IFNα
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) BRII-179, BRII-835 (VIR-2218), PEG-IFNα - Chronic Hepatitis B Virus (HBV) Infection | Phase 2 | Recruiting | Brii Biosciences Limited | 250 | 2024-10-31 | 2026-10-22 |
| Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) BRII-179, BRII-835 (VIR-2218), PEG-IFNα - For Treatment of Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 150 | 2024-08-06 | 2026-10-21 |
| ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα - Chronic Hepatitis b | Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2024-05-21 | 2026-09-01 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) Anti-PD-1 antibody, NAs, Peg-IFNα - Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2023-10-10 | 2026-09-04 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) anti-PD-1/anti-PD-L1 antibody, NAs, PEG-IFNα - Chronic Hepatitis B, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 1200 | 2023-10-10 | 2026-09-28 |
| Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients PEG-IFNα, BRII-835 - Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 86 | 2023-08-22 | 2026-10-20 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 33 | 2023-05-10 | 2026-02-09 |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection VIR-2218, VIR-3434, PEG-IFNα - Hepatitis B, Chronic | Phase 2 | Completed | Vir Biotechnology, Inc. | 244 | 2021-07-11 | 2026-04-23 |
| A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection ABI-H0731, ETV, Peg-IFNα - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 54 | 2021-02-18 | 2023-10-06 |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection VIR-2218, pegylated interferon-alfa 2a - Chronic Hepatitis B | Phase 2 | Completed | Vir Biotechnology, Inc. | 84 | 2020-07-03 | 2026-04-16 |
Hepatitis B, Chronic (9) · Hepatitis B (4) · Hepatitis (3) · Infections (1)
Brii Biosciences Limited (3) · The Second Affiliated Hospital of Chongqing Medical University (3) · Vir Biotechnology, Inc. (3) · Assembly Biosciences (1)
China (7) · South Korea (4) · Hong Kong (3) · Australia (2) · Malaysia (2) · Moldova (2) · New Zealand (2) · Romania (2) · Thailand (2) · United Kingdom (2) · Canada (1) · France (1) · Germany (1) · Singapore (1) · Taiwan (1)
Hong Ren, MM (3) · Grace Wang, MD (1)